Tag: pharmaceuticals

  • iPhone App Developed for Adult Immunization Schedules

    The American College of Physicians (ACP) in Philadelphia has released an application for the iPhone and iPad that provides clinicians with the latest guidance on vaccines for their patients. The free app, for which no Android version is yet available, was written for ACP by medical systems developer Cientis Technologies and Web app designer Hot…

  • Bristol-Myers Squibb Buys Amylin, Expands AstraZenca Deal

    The pharmaceutical company Bristol-Myers Squibb in Princeton, New Jersey will acquire diabetes drug maker Amylin Pharmaceuticals in San Diego, California for $31.00 per share or $5.3 billion. Bristol-Myers Squibb will also expand its current collaboration with pharmaceutical maker AstraZeneca in London developing diabetes drugs, using the assets acquired through Amylin. Amylin Pharmaceuticals is expected to…

  • Biogen Idec, Isis Pharma Partner on Muscular Dystrophy Drug

    The biotechnology companies Biogen Idec in Weston, Massachusetts and Isis Pharmaceuticals in Carlsbad, California have agreed to develop and commercialize an antisense treatment for myotonic dystrophy type 1, also known as Steinert disease. The deal, which involves Biogen Idec licensing antisense technology developed by Isis Pharmaceuticals, will gain Isis $12 million immediately and up to…

  • Study: Better Placebo Info Needed for Drug Trials

    An analysis of pamphlets used to inform patients in clinical trials about the studies in which they take part indicates the literature short-changes discussion of placebos, in favor of the treatments being tested. The findings of health researchers led by psychology professor Felicity Bishop (pictured right) at University of Southampton in the U.K. appear in…

  • Process Devised to Manipulate Organic Molecules in Drugs

    Chemists at Scripps Research Institute in La Jolla, California have developed new techniques they say make it easier to manipulate organic molecules in drug compounds and other chemicals. The team led by Scripps chemistry professor Jin-Quan Yu published its results this week in the online issue of the journal Nature (paid subscription required). Yu, with…

  • Roche to Close N.J. Research Labs, Cut 1,000 Jobs

    The pharmaceutical company Roche, based in Switzerland, says it will close its research labs in Nutley New Jersey, resulting in the loss of 1,000 jobs. The company also says it plans to open a new, but smaller, translational research support facility on the east coast of the U.S. next year. The company says the company-wide…

  • FDA Approves Drug to Manage Spinal Cord Injury Pain

    Pfizer Inc. in New York says the U.S. Food and Drug Administration (FDA) has approved its drug pregabalin, marketed as Lyrica, to manage neuropathic pain associated with spinal cord injury. The drug was given a priority review by FDA. Spinal cord injuries can happen to young, healthy people as a result of trauma from car…

  • NC State, Strasbourg Institutes to Advance Biomanufacturing

    North Carolina State University in Durham and University of Strasbourg in France, along with the Alsace BioValley cluster in Europe, are forming Biomanufacturing Training and Education Center (BTEC) International, to provide educational and regulatory advisory services in the U.S. and Europe. BTEC International will initially combine the resources of NC State’s Golden LEAF Biomanufacturing Training…

  • GSK Licenses Nanotech Product Development Platform

    The global pharmaceutical company GlaxoSmithKline (GSK) will license a nanotechnology-based product development platform created by Liquidia Technologies in North Carolina. The precise financial scale of the deal was not disclosed, but the companies say total earnings by Liquidia could reach as high as several hundred million dollars. Liquidia has built a development technology for pharmaceuticals…

  • Roche, Seaside Therapeutics to Partner on Autism, Fragile X

    Seaside Therapeutics in Cambridge, Massachusetts and the Swiss pharmaceutical company Roche will collaborate to develop treatments for autism spectrum disorders and fragile X syndrome. Financial terms of the agreement were not disclosed. Autism spectrum disorders and fragile X syndrome are neurodevelopmental disorders for which there are no effective treatments yet that address core symptoms. Autism…